CA-PEGASUS-TECH
10.3.2021 13:02:13 CET | Business Wire | Press release
Pegasus Tech Ventures (“Pegasus”), a global venture capital firm based in Silicon Valley, announced a partnership with Japan’s television shopping giant Japanet Holdings (“Japanet”) to establish a $50 million corporate venture capital fund to invest in innovative startups around the globe.
Japanet, headquartered in Nagasaki, Japan, is well-known for its home shopping services and now is expanding into other business sectors. The company recently started a new project to build “Stadium City” in Nagasaki, Japan, which will open in 2024. Centered on a sports stadium, the project includes the development of mixed-use facilities such as business offices, retail stores, hotels, and live event arenas, aiming to make it a Nagasaki landmark that will revitalize the local and regional community. Japanet is also committed to the enrichment of elderly life and to providing educational support for children around the globe.
Through the fund with Pegasus, Japanet aims to create value by funding new ideas and collaborating with startups that develop innovative technologies. The fund plans to invest in Silicon Valley and other parts of North America, as well as in Israel, Europe and Asia.
“We at Japanet Group would like to find high-potential startups with talented entrepreneurs and help them succeed and contribute real value to the world. Using a venture fund, we would like to find cutting edge startup technologies that we can use in the Nagasaki 'Stadium City' project, so that we can provide new services, such as child education, elder care, hospitality, and other services that can help with the betterment of people’s lives,” said Akito Takata, President and CEO of Japanet.
"We will leverage our global network to introduce Japanet to top-tier startups,” said Anis Uzzaman, Founder and CEO of Pegasus Tech Ventures. “By making the connection, both the startups and Japanet benefit. Our goal is to create a global innovation platform that supports the growth of our portfolio companies and the success of our corporate partners.”
Pegasus will deploy its team in Silicon Valley and in 15 other regions around the world to find the best startups and connect them with Japanet and Pegasus’ extensive network of corporate partners.
Pegasus has established venture investment funds with over 35 global corporations, including Aisin Seiki, Sojitz Corporation, SEGA SAMMY HOLDINGS, Sunny Health, CAC Holdings Corporation, Teijin Limited, Infocom Corporation, Innotech Corporation, and ASUS, among others.
About Japanet Holdings Co., Ltd.
Based on a corporate vision, "The joy of living now," Japanet operates a home shopping business, as well as a major sports related business designed to revitalize the local and regional community. In order to enrich the "now," Japanet is also working to enhance healthcare services and to address other social issues, such as educational support for children around the world, and support for disaster-stricken areas. For more information, please visit the website https://corporate.japanet.co.jp/ .
About Pegasus Tech Ventures
Pegasus Tech Ventures is a global venture capital firm based in Silicon Valley with $1.5 Billion in Assets Under Management. Pegasus offers intellectual and financial capital to emerging technology companies around the world. In addition to offering institutional investors a top-tier venture capital investment approach, Pegasus also offers a unique Venture Capital-as-a-Service (VCaaS) model for large, global corporations that wish to partner with cutting-edge technology startups. Some of the 35+ corporate partners that have signed up to work with Pegasus include ASUS, Aisin, SEGA, Sojitz, and Omron. These corporations are able to have access to 180+ Pegasus portfolio companies such as SpaceX, 23andMe, SoFi, Bird, Color, App Annie, and many more. To learn more, visit www.pegasustechventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom